SEC Form 4 · accession 0001447028-26-000039
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A Beardsley
Director
Period of report
Jun 8, 2026
Accepted (ET)
Jun 10, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $4.24 | Jun 8, 2026 | A | 78,800 | A | Jun 8, 2026 | Jun 8, 2036 | Common Shares | 78,800 | 78,800 | D |
Explanation of responses
- F1Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
- F2The option is fully vested and exercisable as of the date of the grant.